In support of the concept that platinum-based chemotherapy and PARP inhibition target the same BRCA-sensitive DNA repair mechanism, replication-associated HR, a correlation between responsiveness towards the two types of treatment was observed in ovarian carcinoma patients [168]. The gene discussed is PARP1; the disease is ovarian carcinoma.